{"id":3827,"date":"2026-03-02T21:32:21","date_gmt":"2026-03-02T21:32:21","guid":{"rendered":"http:\/\/localhost:10028\/resources\/slipstream-coescribe-el-primer-estudio-integral-de-costos-sobre-la-telangiectasia-hemorragica-hereditaria-en-el-american-journal-of-hematology\/"},"modified":"2026-06-19T12:56:03","modified_gmt":"2026-06-19T12:56:03","slug":"slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology","status":"publish","type":"resource","link":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","title":{"rendered":"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology"},"content":{"rendered":"<section id=\"hero-6a58288ab6cb8\"\n         class=\"centered-hero d-flex align-items-center text-center centered-hero--no-cards\"\n         style=\"background-color:#0f2060;--hero-video-overlay:rgba(0,0,0,0.35)\">\n\n    \n    \n    \n    <div class=\"container py-5 hero-content\">\n        <div class=\"row justify-content-center\">\n            <div class=\"col-xl-12\">\n\n                \n                                            <p class=\"mb-3 kicker\" style=\"\">\n                            Comunicado de prensa                        <\/p>\n                    \n                                            <h1 class=\"fw-bold display-3 mb-3 title\" style=\"margin-left:auto;margin-right:auto\">\n                            Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology                        <\/h1>\n                    \n                    \n                    \n                    \n                \n            <\/div>\n        <\/div>\n    <\/div>\n<\/section>\n<div class=\"wp-block-columns are-vertically-aligned-center column-lines-bg is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\"><\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\"><\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Blue Bell, PA \u2013 10 de julio de 2025<\/strong>\u00a0\u2013 Slipstream, un socio tecnol\u00f3gico de confianza que presta servicios a la industria farmac\u00e9utica y biofarmac\u00e9utica, se enorgullece de anunciar su coautor\u00eda de un estudio innovador sobre la telangiectasia hemorr\u00e1gica hereditaria (HHT), publicado recientemente en el\u00a0<em>American Journal of Hematology<\/em>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El estudio,\u00a0<em>\u00abCaracterizaci\u00f3n de la utilizaci\u00f3n de la atenci\u00f3n sanitaria y los costos de la telangiectasia hemorr\u00e1gica hereditaria\u00bb<\/em>, es el estudio m\u00e1s amplio de pacientes con HHT jam\u00e1s realizado, e incluye a m\u00e1s de 24.000 pacientes que viven con este raro trastorno hemorr\u00e1gico hereditario. La investigaci\u00f3n revela que, en esta muestra, los costos m\u00e9dicos directos de la HHT superaron los 450 millones de d\u00f3lares anuales en Estados Unidos, impulsados principalmente por el tratamiento de las complicaciones relacionadas con el sangrado, incluida la anemia ferrop\u00e9nica.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-\"><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00ab<\/strong>Al aprovechar Healthcare Map<sup>\u00ae<\/sup> de Komodo Health, que incluye datos de m\u00e1s de 330 millones de pacientes de EE. UU., hemos podido caracterizar una enfermedad rara cuya historia natural y carga nunca hab\u00edan estado bien definidas ni se hab\u00edan comprendido plenamente,<strong>\u00ab<\/strong>\u00a0dijo\u00a0<strong><strong>Tracy J. Mayne, PhD<\/strong><\/strong>, vicepresidente s\u00e9nior de Investigaci\u00f3n Regulatoria y de Ciencias de la Vida de Slipstream.\u00a0<strong>\u00ab<\/strong>Ahora sabemos que casi el 60% de los pacientes diagnosticados con HHT presentan un sangrado tan grave que causa anemia, y una parte significativa de esos pacientes recibe con frecuencia hierro intravenoso y\/o transfusiones de gl\u00f3bulos rojos. La carga tanto para los pacientes como para el sistema sanitario es enorme, con importantes implicaciones para la defensa de los pacientes y el desarrollo de f\u00e1rmacos.<strong>\u00ab<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El equipo de investigaci\u00f3n, que incluye colaboradores del Massachusetts General Hospital, Cure HHT y Diagonal Therapeutics, utiliz\u00f3 datos de reclamaciones del mundo real de Komodo para evaluar la carga econ\u00f3mica de la enfermedad en una cohorte de m\u00e1s de 24.000 pacientes en 2022 y 2023.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los hallazgos clave de la publicaci\u00f3n incluyen:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cabe destacar que la prevalencia del trasplante hep\u00e1tico entre los pacientes con HHT, derivada de complicaciones de las MAV hep\u00e1ticas, fue 40 veces mayor que en la poblaci\u00f3n general de EE. UU.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los costos por paciente por a\u00f1o (PPPY) para las personas que viven con HHT son comparables a, o superan, los de otras enfermedades raras y de alto consumo de recursos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El sangrado y sus consecuencias se identificaron como los principales factores de los costos sanitarios.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los costos medios PPPY para todos los pacientes con HHT fueron &gt;$19,000 en 2022 y 2023, aproximadamente un 20% superiores a los de la enfermedad de c\u00e9lulas falciformes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los pacientes con HHT y anemia, si bien representan casi el 60% de la poblaci\u00f3n de pacientes con HHT, fueron responsables de aproximadamente el 80% de los costos m\u00e9dicos directos.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00ab<\/strong>Slipstream fue fundada con la convicci\u00f3n de que la tecnolog\u00eda debe empoderar a la industria de las ciencias de la vida para avanzar m\u00e1s r\u00e1pido, trabajar de forma m\u00e1s inteligente y operar con mayor eficiencia,<strong>\u00ab<\/strong>\u00a0dijo\u00a0<strong>Brandon McKay<\/strong>, director ejecutivo de Slipstream.\u00a0<strong>\u00ab<\/strong>Estudios como este validan c\u00f3mo los datos adecuados, junto con la experiencia correcta, pueden redefinir lo que es posible en la atenci\u00f3n sanitaria. Esta colaboraci\u00f3n es exactamente el tipo de trabajo que nos esforzamos por hacer, asoci\u00e1ndonos con innovadores de todo el ecosistema para liberar el poder de los datos del mundo real y las plataformas digitales. Nuestro objetivo siempre es acelerar el impacto donde m\u00e1s importa, mejorando los resultados de los pacientes.<strong>\u00ab<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Este estudio hist\u00f3rico aporta pruebas cr\u00edticas del alto nivel de necesidad no cubierta de los pacientes que viven con HHT, que cuentan con pocas opciones de tratamiento y ning\u00fan medicamento aprobado que modifique la enfermedad o que pueda ralentizar o detener su progresi\u00f3n. Este estudio refuerza el caso para el desarrollo terap\u00e9utico futuro y es un ejemplo del valor que la evidencia del mundo real y la base de datos de Komodo Health aportan al \u00e1mbito de las enfermedades raras.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El art\u00edculo completo est\u00e1 disponible en l\u00ednea a trav\u00e9s del\u00a0<em>American Journal of Hematology<\/em>:\u00a0<a href=\"https:\/\/doi.org\/10.1002\/ajh.27756\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1002\/ajh.27756<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acerca de Slipstream<\/strong><br \/>Slipstream es un socio tecnol\u00f3gico de confianza que presta servicios exclusivamente a la industria de las Ciencias de la Vida. Nuestro equipo global aporta una profunda experiencia en el sector y soluciones pragm\u00e1ticas de extremo a extremo que simplifican desaf\u00edos complejos a lo largo de todo el ciclo de vida del producto. Entregamos con rapidez, cumplimiento normativo y previsi\u00f3n, permitiendo a los clientes acelerar la investigaci\u00f3n, optimizar el tiempo de llegada al mercado y mejorar los resultados de los pacientes, garantizando que la tecnolog\u00eda se mantenga al ritmo de su misi\u00f3n que cambia vidas.\u00a0<a href=\"https:\/\/www.slipstream-it.com\/\">Conozca m\u00e1s sobre Slipstream IT<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acerca de la pr\u00e1ctica Digital CRO de Slipstream<\/strong><br \/>La pr\u00e1ctica Digital CRO de Slipstream est\u00e1 impulsando el desarrollo de f\u00e1rmacos mediante el uso de datos del mundo real y la ciencia de datos actual para crear controles externos\/sint\u00e9ticos e h\u00edbridos mundo real\/placebo como base principal para la aprobaci\u00f3n de medicamentos desarrollados para tratar enfermedades raras. Como l\u00edder del mercado en plataformas digitales farmac\u00e9uticas, Slipstream combina una profunda experiencia terap\u00e9utica con experiencia regulatoria en el mundo real y tecnolog\u00eda l\u00edder en el sector para ayudar a las empresas de enfermedades raras a lograr la aprobaci\u00f3n m\u00e1s r\u00e1pido y a un costo significativamente reducido. Mediante grandes bases de datos nacionales, Slipstream tambi\u00e9n ayuda en la identificaci\u00f3n de centros y la captaci\u00f3n de pacientes para ensayos de enfermedades raras.  <a href=\"https:\/\/www.slipstream-it.com\/cro\">Conozca m\u00e1s sobre nuestra pr\u00e1ctica Digital CRO l\u00edder del mercado<\/a><\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:25%\"><\/div>\n<\/div>\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Blue Bell, PA \u2013 10 de julio de 2025\u00a0\u2013 Slipstream, un socio tecnol\u00f3gico de confianza que presta servicios a la industria farmac\u00e9utica y biofarmac\u00e9utica, se enorgullece de anunciar su coautor\u00eda de un estudio innovador sobre la telangiectasia hemorr\u00e1gica hereditaria (HHT), publicado recientemente en el\u00a0American Journal of Hematology. El estudio,\u00a0\u00abCaracterizaci\u00f3n de la utilizaci\u00f3n de la atenci\u00f3n [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":3291,"template":"","resource_type":[90],"business_need":[114,118,122,126],"service_type":[13],"topic":[134],"class_list":["post-3827","resource","type-resource","status-publish","has-post-thumbnail","hentry","resource_type-article-es","business_need-emerging-biotech-es","business_need-large-pharma-es","business_need-rare-disease-innovators-es","business_need-small-mid-sized-healthcare-es","service_type-digital-cro-offerings","topic-clinical-it-solutions-es"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.1 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology &#062; Slipstream LS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology\" \/>\n<meta property=\"og:description\" content=\"Blue Bell, PA \u2013 10 de julio de 2025\u00a0\u2013 Slipstream, un socio tecnol\u00f3gico de confianza que presta servicios a la industria farmac\u00e9utica y biofarmac\u00e9utica, se enorgullece de anunciar su coautor\u00eda de un estudio innovador sobre la telangiectasia hemorr\u00e1gica hereditaria (HHT), publicado recientemente en el\u00a0American Journal of Hematology. El estudio,\u00a0\u00abCaracterizaci\u00f3n de la utilizaci\u00f3n de la atenci\u00f3n [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/\" \/>\n<meta property=\"og:site_name\" content=\"Slipstream LS\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-19T12:56:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png\" \/>\n\t<meta property=\"og:image:width\" content=\"809\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/\",\"name\":\"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology &#062; Slipstream LS\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/hht-pr.png\",\"datePublished\":\"2026-03-02T21:32:21+00:00\",\"dateModified\":\"2026-06-19T12:56:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/hht-pr.png\",\"contentUrl\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/hht-pr.png\",\"width\":809,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Resources\",\"item\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/resources\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/\",\"name\":\"Slipstream\",\"description\":\"Life sciences, accelerated. Expertise delivered.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/#organization\",\"name\":\"Slipstream LS\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/slipstream-life-sciences-mark.jpg\",\"contentUrl\":\"https:\\\/\\\/www.slipstreamls.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/slipstream-life-sciences-mark.jpg\",\"width\":1200,\"height\":1200,\"caption\":\"Slipstream LS\"},\"image\":{\"@id\":\"https:\\\/\\\/www.slipstreamls.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/slipstreamls\\\/posts\\\/?feedView=all\"],\"description\":\"Slipstream is a life sciences technology partner focused on intelligent, compliant, and trusted execution across R&D, enterprise platforms, data, and operations. We help organizations accelerate research, optimize operations, and implement technology that keeps pace with life-changing missions in an increasingly complex regulatory environment.\",\"email\":\"info@slipstreamls.com\",\"telephone\":\"+1-267-705-4000\",\"legalName\":\"Slipstream IT, LLC\",\"foundingDate\":\"2020-01-01\",\"naics\":\"5415\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":\"501\",\"maxValue\":\"1000\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology &#062; Slipstream LS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","og_locale":"es_ES","og_type":"article","og_title":"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology","og_description":"Blue Bell, PA \u2013 10 de julio de 2025\u00a0\u2013 Slipstream, un socio tecnol\u00f3gico de confianza que presta servicios a la industria farmac\u00e9utica y biofarmac\u00e9utica, se enorgullece de anunciar su coautor\u00eda de un estudio innovador sobre la telangiectasia hemorr\u00e1gica hereditaria (HHT), publicado recientemente en el\u00a0American Journal of Hematology. El estudio,\u00a0\u00abCaracterizaci\u00f3n de la utilizaci\u00f3n de la atenci\u00f3n [&hellip;]","og_url":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","og_site_name":"Slipstream LS","article_modified_time":"2026-06-19T12:56:03+00:00","og_image":[{"width":809,"height":1080,"url":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"5 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","url":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/","name":"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology &#062; Slipstream LS","isPartOf":{"@id":"https:\/\/www.slipstreamls.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#primaryimage"},"image":{"@id":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","datePublished":"2026-03-02T21:32:21+00:00","dateModified":"2026-06-19T12:56:03+00:00","breadcrumb":{"@id":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#primaryimage","url":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","contentUrl":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/02\/hht-pr.png","width":809,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.slipstreamls.com\/es\/resources\/slipstream-co-authors-first-comprehensive-cost-study-on-hereditary-hemorrhagic-telangiectasia-in-the-american-journal-of-hematology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.slipstreamls.com\/es\/"},{"@type":"ListItem","position":2,"name":"Resources","item":"https:\/\/www.slipstreamls.com\/es\/resources\/"},{"@type":"ListItem","position":3,"name":"Slipstream coescribe el primer estudio integral de costos sobre la telangiectasia hemorr\u00e1gica hereditaria en el American Journal of Hematology"}]},{"@type":"WebSite","@id":"https:\/\/www.slipstreamls.com\/es\/#website","url":"https:\/\/www.slipstreamls.com\/es\/","name":"Slipstream","description":"Life sciences, accelerated. Expertise delivered.","publisher":{"@id":"https:\/\/www.slipstreamls.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.slipstreamls.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.slipstreamls.com\/es\/#organization","name":"Slipstream LS","url":"https:\/\/www.slipstreamls.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.slipstreamls.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/03\/slipstream-life-sciences-mark.jpg","contentUrl":"https:\/\/www.slipstreamls.com\/wp-content\/uploads\/2026\/03\/slipstream-life-sciences-mark.jpg","width":1200,"height":1200,"caption":"Slipstream LS"},"image":{"@id":"https:\/\/www.slipstreamls.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/slipstreamls\/posts\/?feedView=all"],"description":"Slipstream is a life sciences technology partner focused on intelligent, compliant, and trusted execution across R&D, enterprise platforms, data, and operations. We help organizations accelerate research, optimize operations, and implement technology that keeps pace with life-changing missions in an increasingly complex regulatory environment.","email":"info@slipstreamls.com","telephone":"+1-267-705-4000","legalName":"Slipstream IT, LLC","foundingDate":"2020-01-01","naics":"5415","numberOfEmployees":{"@type":"QuantitativeValue","minValue":"501","maxValue":"1000"}}]}},"_links":{"self":[{"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/resource\/3827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/resource"}],"about":[{"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/types\/resource"}],"author":[{"embeddable":true,"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/users\/6"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/media\/3291"}],"wp:attachment":[{"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/media?parent=3827"}],"wp:term":[{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/resource_type?post=3827"},{"taxonomy":"business_need","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/business_need?post=3827"},{"taxonomy":"service_type","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/service_type?post=3827"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.slipstreamls.com\/es\/wp-json\/wp\/v2\/topic?post=3827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}